Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR  + , HER2- metastatic breast cancer patients in Japan

CONCLUSIONS: In a routine clinical practice setting in Japan, patients with HR + , HER2- MBC appear to benefit from abemaciclib treatment in terms of treatment response and median PFS, with the results broadly reflecting the evidence demonstrated in clinical trials.PMID:37217763 | DOI:10.1007/s12282-023-01461-6

Source: Breast Cancer - May 22, 2023 Category: Cancer & Oncology Authors: K Nozawa M Terada M Onishi Y Ozaki T Takano W Fakhouri D Novick J M Haro L H Faris T Kawaguchi Y Tanizawa Junji Tsurutani Source Type: research